

ELEVATE High-Risk PCI Pivotal Study

NCT07001332

Status	RECRUITING
Phase	Not Applicable
Sponsor	Magenta Medical Ltd.
Enrollment	290 participants

Key Eligibility Criteria

Inclusion (3)

- Non-emergent, percutaneous coronary intervention is planned on at least one stenotic lesion of a native coronary artery or bypass graft (de novo or restenosis).
- A heart team that includes an interventional cardiologist and cardiac surgeon has determined that HR- PCI is an appropriate therapeutic option.
- Participant signed the informed consent.

Exclusion (17)

- Cardiogenic shock or acutely decompensated pre-existing chronic heart failure.
- Prior stroke with any permanent, significant (mRS \geq 2) neurological deficit, or stroke or TIA within 3 months prior to enrollment.
- Any condition or scheduled surgery that will require discontinuation of the antiplatelet and/or anticoagulation therapy within 90 days of the index procedure.
- Evidence of left ventricular thrombus.
- Aortic valve stenosis/calcification (valve area \leq 1.5 cm²).

... and 12 more (see full listing online)

Locations (28 total)

HonorHealth Scottsdale Shea Medical Center, Scottsdale, Arizona, United States
University of California at San Francisco Medical Center, San Francisco, California, United States
Tampa General/USF, Tampa, Florida, United States

... and 25 more locations